Evaluation imagery representing expert review of pharmaceutical AI claims and references.

Pharma AI evaluation · · 7 min read

How to evaluate AI for MLR review

Acumen Editorial · Updated November 21, 2026

MLR review is the next pharma workflow to get agents. In June 2026, Veeva acquired Copli and launched Veeva Falcon MLR, a tool that checks promotional and medical materials against approved labels and local regulations. Veeva says it could eliminate 70 percent or more of manual MLR labor within five years. Other vendors are making similar pitches: faster pre-review, automatic reference checks and fewer review cycles.

The stakes also went up this month. On November 11, 2026, a Mount Sinai-led study in The Lancet Digital Health tested 12 AI models on 33 physician-written cases, with and without a clearly labeled drug ad. Across 258,559 responses, models picked the advertised drug 47.6 percent of the time with the ad, against 35 percent without it. Promotional content no longer reaches only people. It reaches the models people ask.

So the question for MLR leaders is not whether AI will touch review. It is which checks to hand it, and how to prove it catches what your reviewers catch. Here is how we would test it.

Which MLR checks can AI support today?

IQVIA's Pharma Review team listed the tasks agents could take on in a July 2026 post: checking content against approved claims, checking references, flagging compliance issues, spotting inconsistencies and running standard quality checks. Those are pattern tasks with a clear source of truth. That makes them testable.

Here is how we split the work:

  • Claim matching. Does every claim map to an approved claim in your library, with the same meaning and qualifiers?
  • Reference support. Does the cited page and passage actually support the statement, at the strength stated?
  • Label consistency. Is the content consistent with the current label, indication and population?
  • Fair balance and safety. Is risk information present, prominent and complete enough for the format?
  • Market rules. Does the piece meet local code requirements for the country and audience?
  • Housekeeping. Footnotes, abbreviations, version control and required statements.

Each check fails in a different way, so each needs its own test.

Why can't you trust a single accuracy score?

Because the misses that matter are rare, and averages hide them. A tool can catch every missing footnote and still let an off-label implication through. The second error is the one that becomes a regulatory problem.

Vendor demos also run on clean content. Real MLR queues have localized versions, edited claims, image-only text and references that were updated last quarter. IQVIA names the common reference library problems: duplicate documents, outdated materials, inconsistent metadata and limited traceability. As the post puts it, "AI can only be as effective as the information that supports it." If your test set skips that mess, your results will not survive production.

Who should grade an MLR AI tool?

Your reviewers, not another model. A 2026 preprint by researchers at UCSF, Harvard Medical School and other institutions had 149 practicing physicians grade answers from four clinical AI systems. LLM judges usually agreed with physicians on the top system but not on the rest of the ranking. Rank correlations ranged from negative to moderate, and one judge favored its own model.

MLR judgment is harder to automate than that. A medical reviewer reads for clinical meaning, a regulatory reviewer reads for label and code, and a legal reviewer reads for risk. Grade each check with the discipline that owns it, blind to which tool produced the comment, with a second reviewer on disagreements.

Where must humans stay in the loop?

Approval. In the UK, IQVIA notes, PMCPA guidance says AI can support compliance work but does not relieve companies of their ABPI Code responsibilities, and certification by a nominated signatory cannot be met through AI alone. US teams work under the same basic logic: the company owns what it promotes.

Teams seem ready for the help. A Veeva survey of 101 content professionals across 10 biopharmas found more than half had no concerns about AI in promotional review. But 48 percent named areas that need attention: accuracy and reliability, compliance and auditability, data privacy and security, and human oversight. Those four areas are your evaluation plan.

How should you build an MLR evaluation set?

Build it from your own history, privately. Here is the checklist we use:

  • Define the approved use. Which checks the tool runs, on which content types and markets, and what it never decides.
  • Use past submissions with known outcomes. Pull de-identified pieces with the comments your reviewers actually made.
  • Seed known errors. Plant unsupported claims, wrong references, missing safety information and off-label implications you already have answers for.
  • Include the messy cases. Localized versions, image text, short-form social, HCP and patient versions of the same claim.
  • Write reference comments. For each seeded error, the comment a senior reviewer would write and its severity.
  • Grade blind by discipline. Medical, legal and regulatory reviewers score the checks they own. Adjudicate disagreements and report agreement.
  • Test with and without promotional context. If a tool also answers medical questions, check whether your own content shifts its answers, as the Mount Sinai team recommends.
  • Document everything. Plan, results and deviations belong in your quality records.
  • Rerun on every change. New model, new label, new claims library or new market means a new run.

Which metrics matter for each MLR check?

Pick the metric that matches the error that hurts most.

CheckFailure that mattersPrimary metricWho grades
Claim matchingUnapproved claim passesRecall on seeded unapproved claimsRegulatory reviewers
Reference supportClaim overstates the sourcePrecision and recall on seeded unsupported referencesMedical reviewers
Label consistencyOff-label implication passesRecall on seeded off-label contentMedical and regulatory reviewers
Fair balance and safetyMissing or buried risk informationRecall on seeded omissions, by formatRegulatory and legal reviewers
Market rulesLocal code breach passesRecall by marketLocal regulatory reviewers
All checksNoise that slows reviewersFalse flags per pieceReview coordinators

Report misses by severity, not just in total. One missed off-label implication outweighs a hundred caught footnotes.

What should you ask an MLR AI vendor?

Ask for evidence, not a demo:

1. Which checks was the tool tested on, and on whose content?

2. Who wrote the reference comments, and what are their roles and credentials?

3. What is recall on high-severity errors, reported separately from overall accuracy?

4. How many false flags does a reviewer see per piece?

5. Which version of our claims library and label does each comment rely on?

6. Can we run our own private evaluation set before go-live and after every update?

7. What audit trail exists for each AI comment, reviewer edit and approval?

How Acumen helps

We build the evaluation and training data behind regulated pharma AI. Our medical affairs and regulatory data service supplies private MLR evaluation sets written and graded by medical, regulatory and promotional review experts: seeded error sets, reference comments with severity, blind graded runs and regression tests on every release. Every item is reviewed and adjudicated.

Use it to test a vendor's tool, to tune your own, or both. For how medical information teams test the AI answers HCPs see first, read our guide to AI for medical affairs.

Request a sample dataset Schedule a conversation

FAQ

What is AI used for in MLR review?

Mostly pre-review checks. Teams use AI to match claims to an approved claims library, check that references support statements, flag label inconsistencies and missing safety information, and catch housekeeping errors. IQVIA's Pharma Review team, writing in July 2026, framed these as tasks agents can support while expert reviewers keep the judgment calls.

Can AI approve promotional materials?

No. AI can flag issues and draft comments, but a qualified person still approves. In the UK, PMCPA guidance cited by IQVIA says AI does not relieve companies of ABPI Code responsibilities and certification by a nominated signatory cannot be met through AI alone. Treat AI comments as input to your reviewers, not a decision.

How accurate is AI at MLR review?

There is no single answer, and you should distrust anyone who gives one. Accuracy depends on the check, the content type and the state of your claims and reference libraries. Ask for recall on seeded high-severity errors, false flags per piece and results on your own past submissions, graded by your reviewers.

How do you build a test set for MLR AI?

Start from de-identified past submissions with the comments your reviewers made. Seed known errors: unapproved claims, unsupported references, missing safety information and off-label implications. Write a reference comment and severity for each. Have medical, legal and regulatory reviewers grade blind, adjudicate disagreements, and rerun after every model, label or library change.

Why does the Mount Sinai drug ad study matter for MLR teams?

It shows promotional content can shift AI answers. The November 2026 Lancet Digital Health study found models picked an advertised drug in 47.6 percent of responses after seeing an ad, against 35 percent without. If your tools also answer medical questions, test them with and without your own promotional content in context.

Can an LLM grade MLR AI outputs instead of reviewers?

Not on its own. A 2026 preprint found LLM judges matched physicians on the top clinical AI system but disagreed on the rest of the ranking, and one favored its own model. Use model graders to triage volume if you like, but keep medical, legal and regulatory reviewers as the reference and report their agreement.

From the Acumen archive. Explore expert data and Healthcare & Pharma.

← Back to Insights